Mind Medicine (MindMed) Inc. a leading biotech company developing psychedelic-inspired therapies is pleased to announce that it has initiated recruitment for a randomized placebo-controlled trial evaluating the effects of repeated low-dose LSD during the day and evening.
Researchers will use digital measurement equipment and software to measure the effects of microdoses LSD for neuroplasticity markers such as BDNF plasma levels. Measurements are also made on the basis of sleep, mood, cognitive performance, regulation of emotions, quality of life and immune system response. The research will be conducted by Dr. Kim Kuypers of Maastricht University, a leading global authority on the use of low-dose psychedelics.
“Research into the practice of taking repeated low doses of psychedelics starts with the basics, seeing if there is a time of day that influences the impact of these treatments,” said Dr. Kuypers. “We are investigating whether the repeated intake of lower doses could lead to realignment of thought patterns that would allow individuals to access levels of self-awareness that can provide an enriched life experience.”
Microdosing of psychedelics
“There are increasing claims about the so-called 'microdosing' of psychedelics regarding its potential to affect mental and physical well-being, cognition, memory and specific aspects such as creativity and productivity,” said Dr. Miri Halperin Wernli, MindMed's Executive Chairman. “However, there was no scientific evidence to support or even fully investigate the claimed safety and benefits. With our innovative research design, which integrates digital medical measurement techniques with more traditional self-reporting and cognitive tasks, our goal is to provide insight into key parameters. These parameters include differences between day and night and possible cumulative effects due to repeated administration.
About MindMed
MindMed is a clinical-stage psychedelic drug biotech company that seeks to discover, develop, and deploy psychedelic-inspired drugs and therapies to address addiction and mental illness. The company is in the process of compounding and developing drugs based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC.
Read more newswire.ca (Source, EN)
